Members |
targetComponentId |
Legionella bozemanii |
Legionella bozemanae (organism) |
Legionella dumoffii |
Legionella dumoffii |
Legionella gormanii |
Legionella gormanii |
Legionella micdadei |
Legionella micdadei (organism) |
Leigh syndrome with nephrotic syndrome |
Leigh's disease |
Leiomyoma, no International Classification of Diseases for Oncology subtype |
Leiomyoma |
Leiomyomatosis, no International Classification of Diseases for Oncology subtype |
Leiomyomatosis |
Leiomyomatous neoplasm - category |
Leiomyomatous neoplasm |
Leiomyosarcoma - category |
Leiomyosarcoma |
Leiomyosarcoma, no subtype |
Leiomyosarcoma |
Leishmaniacides |
Antiprotozoal |
Lemon - dietary |
Lemon (substance) |
Length of labor NOS |
Duration of labor |
Length of labour NOS |
Duration of labor |
Lenograstim 263micrograms powder and solvent for injection solution vial |
Product containing only lenograstim in parenteral dose form (medicinal product form) |
Lenograstim 263micrograms powder for conventional release solution for injection vial |
Product containing only lenograstim in parenteral dose form (medicinal product form) |
Lepromatous cutaneous leishmaniasis |
Diffuse cutaneous leishmaniasis |
Leptospira inadei |
Leptospira inadai |
Leptospira interrogans interrogans |
Leptospira interrogans |
Leptospirosis due to other specific organisms |
Leptospirosis |
Leptospirosis icterohemorrhagica |
Weil's disease |
Leptospirosis icterohemorrhagica |
Weil's disease |
Leptospirosis risk exposure (& [Weil's disease]) |
At increased risk of exposure to Leptospira |
Leptospirosis risk exposure (& [Weil's disease]) |
At increased risk of exposure to Leptospira |
Leptospirosis risk exposure |
At increased risk of exposure to Leptospira |
Lepus victoriae |
Lepus microtis subspecies microtus (organism) |
Lesion endoscopic destruction NOS |
Endoscopic destruction of lesion (procedure) |
Lesion endoscopic destruction NOS |
Endoscopic destruction of lesion (procedure) |
Lethal neonatal spasticity |
A rare genetic neurological disorder characterized by neonatal onset of rigidity and intractable seizures, with episodic jerking already beginning in utero. Affected infants have small heads, remain visually inattentive, do not feed independently, and make no developmental progress. Frequent spontaneous apnea and bradycardia usually culminate in cardiopulmonary arrest and death in infancy, although some cases were described with a milder clinical course and survival into childhood. |
Letterer-Siwe disease of extranodal AND/OR solid organ site |
Langerhans cell histiocytosis, disseminated (disorder) |
Letterer-Siwe disease of intra-abdominal lymph nodes |
Disseminated Langerhans cell histiocytosis of abdominal lymph nodes (disorder) |
Letterer-Siwe disease of intrapelvic lymph nodes |
Disseminated Langerhans cell histiocytosis of pelvic lymph nodes (disorder) |
Letterer-Siwe disease of intrathoracic lymph nodes |
Disseminated Langerhans cell histiocytosis of lymph nodes of thorax (disorder) |
Letterer-Siwe disease of lymph nodes of axilla AND/OR upper limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of upper limb (disorder) |
Letterer-Siwe disease of lymph nodes of axilla and upper limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of upper limb (disorder) |
Letterer-Siwe disease of lymph nodes of head |
Disseminated Langerhans cell histiocytosis of lymph nodes of head (disorder) |
Letterer-Siwe disease of lymph nodes of inguinal region AND/OR lower limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of lower limb (disorder) |
Letterer-Siwe disease of lymph nodes of inguinal region and lower limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of lower limb (disorder) |
Letterer-Siwe disease of lymph nodes of lower limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of lower limb (disorder) |
Letterer-Siwe disease of lymph nodes of multiple sites |
Disseminated Langerhans cell histiocytosis of lymph nodes of multiple sites (disorder) |
Letterer-Siwe disease of lymph nodes of neck |
Disseminated Langerhans cell histiocytosis of cervical lymph nodes (disorder) |
Letterer-Siwe disease of lymph nodes of upper limb |
Disseminated Langerhans cell histiocytosis of lymph nodes of upper limb (disorder) |
Letterer-Siwe disease of spleen |
Disseminated Langerhans cell histiocytosis of spleen (disorder) |
Letterer-Siwe's disease |
Langerhans cell histiocytosis, disseminated |
Lettuce - dietary |
Lettuce (substance) |
Leucaena glauca |
Leucaena leucocephala |
Leucodystrophy without a known biochemical basis |
Leucodystrophy |
Leuconostoc fructosum |
Fructobacillus fructosus (organism) |
Leuconostoc garviae |
Lactococcus garvieae (organism) |
Leuconostoc oenos |
Oenococcus oeni |
Leuconostoc paramesenteroides |
Weissella paramesenteroides |
Leucotomy NEC |
Leukotomy |
Leukaemia - specif. cell NOS |
Leukaemia |
Leukaemia of unspecified cell type |
Leukaemia |
Leukemia - category |
Leukaemia |
Leukemia - specific cell NOS |
Leukaemia |
Leukemia of unspecified cell type |
Leukaemia |
Leukemia, no International Classification of Diseases for Oncology subtype |
Leukaemia |
Leukemic reticuloendotheliosis |
Hairy cell leukemia |
Leukemic reticuloendotheliosis of extranodal AND/OR solid organ site |
Hairy cell leukemia |
Leuprolide acetate 11.25mg |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Leuprolide acetate 11.25mg injection |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Leuprolide acetate 11.25mg powder for injection suspension vial |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Leuprolide acetate 15mg powder and solvent for injection suspension vial |
Leuprorelin only product in parenteral dose form |
Leuprolide acetate 15mg powder for injection suspension vial |
Leuprorelin only product in parenteral dose form |
Leuprolide acetate 22.5mg |
Leuprorelin only product in parenteral dose form |
Leuprolide acetate 22.5mg powder for injection suspension vial |
Leuprorelin only product in parenteral dose form |
Leuprolide acetate 30mg |
Leuprorelin acetate 20 mg/mL suspension for injection |
Leuprolide acetate 30mg powder for injection suspension vial |
Leuprorelin acetate 20 mg/mL suspension for injection |
Leuprolide acetate 45mg powder for injection suspension vial |
Product containing precisely leuprorelin acetate 120 milligram/1 milliliter conventional release suspension for injection (clinical drug) |
Leuprolide acetate 7.5mg |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Leuprolide acetate 7.5mg injection |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Leuprolide acetate 7.5mg powder for injection suspension vial |
Leuprorelin acetate 7.5 mg/mL suspension for injection |
Levafix black |
Textile colours and finishes patch test substance |
Levafix brilliant blue |
Textile colours and finishes patch test substance |
Levafix brilliant yellow |
Textile colours and finishes patch test substance |
Levafix dye |
Textile colours and finishes patch test substance |
Levafix marinblau |
Textile colours and finishes patch test substance |
Levalbuterol 45mcg hfa metered dose aerosol inhaler |
Product containing only levosalbutamol (medicinal product) |
Levobetaxolol hydrochloride 0.5% ophthalmic suspension |
Levobetaxolol 5 mg/mL eye suspension |
Levobunolol hydrochloride 0.5% conventional release eye drops |
Levobunolol hydrochloride 5 mg/mL eye solution |
Levobunolol hydrochloride 0.5% single-use eye drops |
Levobunolol hydrochloride 5 mg/mL eye solution |
Levobupivacaine 1.25mg/mL injection solution 200mL bag |
Product containing precisely levobupivacaine (as levobupivacaine hydrochloride) 1.25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Levocetirizine 2.5mg/5mL oral solution |
Levocetirizine dihydrochloride 500 microgram/mL oral solution |
Levofloxacin 1.5% ophthalmic solution |
Product containing precisely levofloxacin anhydrous (as levofloxacin) 15 milligram/1 milliliter conventional release eye solution (clinical drug) |
Levofloxacin 25mg/mL oral solution |
Product containing precisely levofloxacin anhydrous (as levofloxacin) 25 milligram/1 milliliter conventional release oral solution (clinical drug) |
Levofloxacin 5mg/mL infusion solution 100mL vial |
Levofloxacin 5 mg/mL solution for injection |
Levofloxacin 5mg/ml ophthalmic solution |
Levofloxacin anhydrous (as levofloxacin) 5 mg/mL eye solution |
Levoleucovorin calcium 50mg powder for injection solution vial |
Levoleucovorin (as levoleucovorin calcium) 50 mg powder for solution for injection vial |
Levomethadyl acetate hydrochloride 10mg/mL oral solution |
Levomethadyl 10 mg/mL oral solution |
Levonorgestrel 0.015mg/day + estradiol 0.045mg/day transdermal system |
Estradiol 1.88 microgram/hour and levonorgestrel 625 nanogram/hour prolonged-release transdermal patch |
Levonorgestrel 52mg intrauterine system |
Product containing precisely levonorgestrel 833 nanogram/1 hour prolonged-release intrauterine drug delivery system (clinical drug) |
Levothyroxine sodium 0.05mg tablet |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
Levothyroxine sodium 0.075mg tablet |
Levothyroxine sodium anhydrous 75 microgram oral tablet |
Levothyroxine sodium 0.1mg tablet |
Levothyroxine sodium anhydrous 100 microgram oral tablet |
Levothyroxine sodium 200mg tablet |
Product containing precisely levothyroxine sodium 200 microgram/1 each conventional release oral tablet (clinical drug) |
Levothyroxine sodium o.05mg |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
Leydig cell neoplasm of testis |
Leydig cell tumor of testis of uncertain behavior |
Leydig cell tumor, no International Classification of Diseases for Oncology subtype |
Leydig cell tumor of uncertain behavior (morphologic abnormality) |
Librarian/info.officer NOS |
Librarian/information officer |
Librarian/information officer NOS (occupation) |
Librarian/information officer |